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Abstract - The methyl 3-amino-6-bromothieno[3,2-b]pyridine-2-carboxylate, recently 
reported by some of us, was reacted in Sonogashira couplings with several 
(hetero)arylacetylenes. The growth inhibitory activity of the novel methyl 3-amino-6-
[(hetero)arylethynyl]thieno[3,2-b]pyridine-2-carboxylates obtained was evaluated on 
three human tumor cell lines (MCF-7, NCI-H460, A375-C5). The para-methoxyphenyl 
and the ortho and para-aminophenyl derivatives were the most promising compounds, 
and their effects were further studied regarding alterations in the normal cell cycle 
distribution and induction of apoptosis in the NCI-H460 cell line. All three compounds 
altered cell cycle distribution and the ortho-aminophenyl derivative was further shown 
to induce apoptosis in the same cell line. 
 
Keywords: Thieno[3,2-b]pyridines, Sonogashira coupling, Antitumoral activity, Cell 
Cycle, Apoptosis 
 
1. Introduction 
Recently several thieno[3,2-b]pyridines have shown important biological activities, 
namely antitumor and antiangiogenesis or dual activity, essentially by acting as 
inhibitors of tyrosine kinase receptors I [1], II [2] III [3], or nonreceptors (IV) [4] 
which have been implicated in the growth and progression of various human cancers 
and, therefore, have been crucial in the development of anticancer therapies.  
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As we have recently prepared the methyl 3-amino-6-bromothieno[3,2-b]pyridine-2-
carboxylate [5]  it was decided to use it in the Pd/Cu-catalysed Sonogashira coupling [6] 
with several terminal (hetero)arylacetylenes in the synthesis of novel methyl 3-amino-6-
[(hetero)arylethynyl]thieno[3,2-b]pyridine-2-carboxylates. Their potential as antitumor 
agents was evaluated through the in vitro growth inhibitory activity on three selected 
human tumor cell lines, MCF-7, NCI-H460, and A375-C5 and some structure-activity 
relationships (SARs) were established. 
For the most promising compounds the effects on the cell cycle distribution and 
induction of apoptosis were studied, in order to investigate their possible mechanisms of 
action. 
 
2. Results and discussion 
2.1 Synthesis 
The 6-bromothieno[3,2-b]pyridine 1 [5] was used as the thieno[3,2-b]pyridine 
component in the Pd/Cu catalyzed Sonogashira reaction [5-7] with several 
(hetero)arylacetylenes to obtain the novel methyl 3-amino-6-
[(hetero)arylethynyl]thieno[3,2-b]pyridine-2-carboxylates 2a-m in high to excellent 
yields using the conditions depicted in Scheme 1, already used by us in the synthesis of 
arylethynyl benzo[b]thiophene derivatives [7]. 
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2a R1 = R2 = R3 = H, 70%
2b R1 = OMe,  R2 = R3 = H, 80%
2c R2 = OMe, R1 = R3 = H, 75%
2d R3 = OMe, R1 = R2 = H, 70%
2e R1 = NH2,  R2 = R3 = H, 70%
2f R2 = NH2, R1 = R3 = H, 60%
2g  R3 = NH2, R1 = R2 = H, 75%
2h R3 = NMe2, R1 = R2 = H, 80%
2i R1 = F,  R2 = R3 = H, 75%
2j  R3 = F, R1 = R2 = H, 90%
2k  R1 = R2 = R3 = H, X = N,70%
2l R1 = R2 = R3 = H, Y = N, 90%
X= Y= CH unless stated
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 Scheme 1. Synthesis of compounds 2a-2m. Conditions: PdCl2(PPh3)2 (5 mol%), CuI (3 mol%), NEt3 (3 
equiv.), DMF, 1.5 h, 100 oC. 
 
 
2.2 Growth inhibition of human tumor cell lines  
The in vitro growth inhibitory activity of all the compounds prepared was evaluated 
using three human tumor cell lines, representing different tumor types, namely breast 
adenocarcinoma (MCF-7), melanoma (A375-C5), and non-small cell lung cancer (NCI-
H460), after a continuous exposure of 48 h. The results are summarized in Table 1. 
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Table 1- Growth inhibitory activity of the 6-(hetero)arylethynylthieno[3,2-b]pyridines 2 
on the three human tumor cell lines in study. 
GI50 (µM)a Compounds 
MCF-7 A375-C5 NCI-H460 
2a >150.0 >150.0 >150.0 
2b >47.3b >47.3b >47.3b 
2c 33.4±4.7 >75.0b 49.0±4.7 
2d 0.46±0.05 >37.5b 0.32±0.05 
2e 4.1±0.7 3.1±2.1 5.7±3.0 
2f 10.8±1.2 11.6±0.6 11.5±0.5 
2g 2.6±1.4 4.8±0.4 8.9±0.9 
2h 20.6±1.1 17.7±0.1 16.6±1.1 
2i >150 >150 >150 
2j 29.0±1.2 48.4±1.6 24.0±2.0 
2k 37.4±4.1 13.9±1.9 34.9±5.4 
2l >150 >150 >150 
2m 27.7±2.7 29.6±0.2 24.8±0.5 
aThe lowest concentrations causing 50% of cell growth inhibition (GI50)  
after a continuous exposure of 48 h, expressed as means ± SEM of three  
independent experiments performed in duplicate. b Due to the low solubility  
of  the compound in DMSO the maximum concentration tested was lower  
than 150 µM. Doxorubicin was used as positive control (GI50: MCF-7 = 43.3 ± 2.6 nM;  
A375-C5 = 130.2 ± 10.1 nM; NCI-H460 = 35.6 ± 1.6 nM). 
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From the analysis of Table 1 it can be concluded that the p-methoxylated compound 2d 
presents the lowest GI50 values (below 1.0 µM), with marked selectivity for MCF-7 and 
NCI-H460 cell lines. The aminated compounds 2e-2g  were also effective at inhibiting 
cell growth, with GI50 values between 2.6-11.6 µM for the three cell lines, the best 
being the o- and p-aminophenyl compounds 2e and 2g. 
The methoxylated compounds 2b and 2c were not very potent at inhibiting cell growth. 
They are not very soluble, nevertheless for compound 2c it was possible to determine 
the GI50 values for MCF-7 and NCI-H460 which were between 33.4 and 49.0 µM. The 
tendency for selective activity excluding the melanoma cell line (A375-C5), which is 
clear for compound 2d, is already detectable in 2c. The p-dimethylamino derivative 2h 
presents higher GI50 values than the free amino compounds. Among the fluorinated 
compounds 2i and 2j only the latter shows moderate GI50 values (24.0-48.4 µM). 
Considering the fact that the unsubstituted phenylacetylene derivative 2a did not show 
any activity at the highest tested concentration, the cell growth inhibitory activity 
presented by the compounds discussed above appears to be closely dependent on the 
substitution pattern. 
The pyridine derivative 2k shows some selectivity against A375-C5 cell line, with a 
GI50 value of 13.9 µM. The position of the C-C bond in the pyridine ring appears to be 
determinant for the cell growth inhibitory activity, since compound 2l was not active at 
the highest concentration tested.  
The thiophene derivative 2m presents moderate growth inhibitory activity against the 
three cell lines in study (GI50 values between 24.8-29.6 µM). 
 
2.3. Cell cycle analysis and detection of apoptosis  
 
The most active compounds were chosen to be further investigated regarding their 
mechanism of action. The NCI-H460 cell line was incubated with the GI50 
concentrations of compounds 2d, 2e and 2g for 48 h and their effects on the normal cell 
cycle distribution and induction of apoptosis analyzed. The results show that all three 
compounds interfere with the normal cell cycle distribution of this cell line. Compound 
2d caused a small increase in the percentage of cells in G0/G1 and a reduction in the 
percentage of cells in the S-phase of the cell cycle (Table 2). A similar but more marked 
effect was observed upon incubation with compound 2g. Compound 2e induced an 
increase in the percentage of cells in G2/M phases of the cell cycle accompanied by a 
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decrease of cells in S-phase (Table 2). From these results it appears that compounds 2d 
and 2g induce a cell cycle arrest on phases G0/G1, whereas compound 2e appears to 
cause a G2/M cell cycle arrest. These compounds were also shown to induce apoptosis, 
as determined by the annexin V-FICT/PI flow cytometry assay, particularly compound 
2e (Table 2). This observation was confirmed by the presence of a sub-G1 peak in the 
cell cycle profile analysis (indicative of DNA degradation, characteristic of apoptosis) 
upon incubation with compound 2e (data not shown). 
 
Table2. Cell cycle analysis (% of cells  in phases G0/G1, S, G2/M)  
and % of NCI-H460 cells undergoing apoptosis after a 48 h treatment  
with compounds 2d, 2e and 2g at their GI50 concentrations.  
 
G0/G1  
(cells %) 
S  
(cells %) 
G2/M  
(cells %) 
Apoptosis  
(cells %) 
Control 57.1 ± 1.6 28.2 ± 1.4 14.7 ± 0.9 11.7 ± 1.6 
DMSO 55.1 ± 1.0 28.8 ± 1.2 16.1 ± 0.9 12.2 ± 1.2 
2d 59.7 ± 3.2 22.0 ± 1.7 18.3 ± 1.9 18.7 ± 2.8 
2e 54.7 ± 2.7 23.1 ± 2.8 24.6 ± 2.4 25.3 ± 1.8a 
2g 68.0 ± 0.7 18.6 ± 0.8 13.4 ± 0.6 17.0 ± 2.1 
Untreated cells were used as the control and a solvent control (DMSO)  
was also included. Results are the mean ± standard error of three to  
six independent experiments performed in duplicate. 
a
 Apoptosis induction by compound 2e was statistically significantly when compared  
to the control (P <0.05). 
 
According to these findings, the compounds are likely to present different mechanisms 
of action. The effect of compound 2e in cell growth inhibition seems to be due to the 
induction of both apoptosis and cell cycle arrest in the G2/M phase (Table2). 
Compounds 2d and 2g did not cause such a marked induction of apoptosis (Table 2) and 
thus their growth inhibitory effects seem to be mainly due to cell cycle related events. 
 
3. Conclusion 
 
Novel methyl 3-amino-6-[(hetero)arylethynyl]thieno[3,2-b]pyridine-2-carboxylates 
were synthesized and tested for their in vitro growth inhibitory activity on three human 
tumor cell lines. All compounds were fully soluble at the GI50 concentration. Overall, 
the para-methoxyphenyl and the ortho and para-aminophenyl derivatives are the most 
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promising compounds, presenting very low GI50 values and therefore their effects on 
cell cycle distribution and induction of apoptosis were further investigated in the NCI-
H460 cell line.  Compounds 2d, 2e and 2g had an effect on cell cycle distribution, with 
a G0/G1 arrest being detected for the para-methoxyphenyl and the para-aminophenyl 
derivatives and a G2/M arrest for the ortho-aminophenyl derivative. Additionally, the 
ortho-aminophenyl compound was found to significantly induce apoptosis at the GI50 
concentration in the tested cell line. Hence, at least two mechanisms of action appear to 
be involved in the activity of this compound, cell cycle related events and induction of 
apoptosis. The obtained data suggest that the results are dependent on the compound 
substitution pattern, nevertheless it is important to bear in mind that the physical 
properties of the compounds, particularly cell permeability, may be influencing their 
relative activity.  
 
 
4. Experimental 
4.1 Synthesis 
 
Melting points (oC) were determined in a SMP3 Stuart apparatus and are uncorrected. 1H and 13C NMR 
spectra were recorded on a Varian Unity Plus at 300 and 75.4 MHz, and on a Bruker Avance II at 400 and 
100.6 MHz, respectively. Heteronuclear correlations, 1H-13C, HMQC or HMSQ and HMBC were 
performed to attribute some signals. MS (EI) and HRMS data were recorded by the mass spectrometry 
service of the University of Vigo, Spain. Elemental analysis was performed on a LECO CHNS 932 
elemental analyser. The reactions were monitored by thin layer chromathography (TLC). Dry flash was 
performed on Macherey-Nagel silica gel 150-230 mesh. Petroleum ether refers to the boiling range 40-60 
oC. Ether refers to diethylether.  
 
4.1.1. General procedure for the synthesis of compounds 2a-2m: 
Compound 1 (150 mg, 0.540 mmol), the (hetero)arylacetylene (1.1 equiv.), PdCl2(PPh3)2 (5 mol%), CuI 
(3 mol%), and NEt3 (3 equiv.) were added to dry DMF (2-3 mL) into a dry Schlenk tube, under argon, 
and the mixture was heated with stirring at 100 ºC for 1.5 h. After cooling, water (5 mL) and ethyl acetate 
(5 mL) were added and the phases were separated. The aqueous phase was then extracted with additional 
ethyl acetate (3 × 5 mL). The organic phases were collected, dried (MgSO4), filtered, and, finally, 
removal of the solvent under reduced pressure gave a solid which was submitted to column 
chromatography using 50% ether/ petroleum ether as eluent. The solid obtained was washed with 
petroleum ether and fully characterized. 
 
4.1.1.1. Methyl 3-amino-6-(2-phenylethynyl)thieno[3,2-b]pyridine-2-carboxylate (2a): Yellow solid 
(117 mg, 70%), m.p. 175-177 ºC. 1H NMR (CDCl3, 400 MHz) δ 3.93 (3H, s, OMe), 6.24 (2H, br s, NH2), 
7.38-7.42 (3H, m, Ar-H), 7.56-7.60 (2H, m, Ar-H), 8.18 (1H, d, J = 2 Hz, Ar-H), 8.73 (1H, d, J = 2 Hz, 
Ar-H) ppm. 13C NMR (CDCl3, 100.6 MHz) δ 51.75 (OMe), 86.07 (C), 93.88 (C), 100.84 (2-C), 
119.11(2×CH), 122.29 (1’-C), 128.50 (2×CH), 129.02 (C), 131.74 (C), 133.49 (CH), 133.72 (C), 144.97 
(3a-C), 147.30 (C), 148.73 (CH), 165.17 (C=O) ppm.  MS (EI) m/z 308 (M+, 100), 276 (66). HRMS M+ 
calcd. for C17H12N2O2S 308.0619; found 308.0624. 
 
4.1.1.2. Methyl 3-amino-6-[2-(2-methoxyphenyl)ethynyl]thieno[3,2-b]pyridine-2-carboxylate (2b): 
Yellow solid (146 mg, 80%), m.p. 193-195 ºC. 1H NMR (CDCl3, 400 MHz) δ 3.92 (3H, s, OMe), 3.95 
(3H, s, OMe), 6.22 (2H br s, NH2), 6.93-6.98 (2H, m, Ar-H), 7.34-7.39 (1H, m, Ar-H), 7.53 (1H, dd, J = 
7.6 and 2 Hz, Ar-H), 8.20 (1H, d, J = 2 Hz, Ar-H), 8.75 (1H, d, J = 2 Hz, Ar-H) ppm. 13C NMR (CDCl3, 
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100.6 MHz) δ 51.71 (OMe), 55.83 (OMe), 90.06 (C), 90.45 (C), 100.68 (2-C), 110.74 (CH), 111.52 (C), 
119.50 (C), 120.57 (CH), 130.57 (CH), 133.38 (CH), 133.65 (CH), 133.67 (C), 144.89 (C), 147.38 (C), 
148.89 (CH), 160.16 (C), 165.21 (C=O) ppm. MS (EI) m/z 338 (M+, 100), 306 (39). HRMS M+ calcd. for 
C18H14N2O3S 338.0725; found 338.0727. 
 
41.1.3. Methyl 3-Amino-6-[2-(3-methoxyphenyl)ethynyl]thieno[3,2-b]piridine-2-carboxylate (2c): 
Yellow solid (137 mg, 75%), m.p. 177-179 ºC. 1H NMR (CDCl3, 400 MHz) δ 3.85 (3H, s, OMe), 3.93 
(3H, s, OMe), 6.23 (2H, br s, NH2), 6.94-6.97 (1H, m, Ar-H), 7.09-7.11 (1H, m, Ar-H), 7.16-7.19 (1H, m, 
Ar-H), 7.30 (1H, app. t, J = 8 Hz, 5’-H), 8.19 (1H, d, J = 1.6 Hz, Ar-H), 8.73 (1H, d, J = 1.6 Hz, Ar-H) 
ppm. 13C NMR (CDCl3, 100.6 MHz) δ 51.74 (OMe), 55.33 (OMe), 85.89 (C), 93.78 (C), 100.84 (2-C), 
115.65 (CH), 116.48 (CH), 119.03 (C), 123.26 (C), 124.29 (CH), 129.58 (5’-CH), 133.49 (CH), 133.69 
(C), 145.05 (C), 147.32 (C), 148.78 (CH), 159.42 (C), 165.18 (C=O) ppm. MS (EI) m/z 338 (M+, 100), 
306 (53). HRMS M+ calcd. for C18H14N2O3S 338.0725; found 338.0723. 
 
4.1.1.4. Methyl 3-amino-6-[2-(4-methoxyphenyl)ethynyl]thieno[3,2-b]pyridine-2-carboxylate (2d): 
yellow solid (130 mg, 70 %), m.p. 190-192 ºC. 1H NMR (CDCl3, 300 MHz): δ 3.85 (3H, s, OMe), 3.92 
(3H, s, OMe), 6.25 (2H, broad s, NH2), 6.92 (2H, d, J = 8.4 Hz, 3’ and 5’-H), 7.52 (2H, d, J = 8,4 Hz, 2’ 
and 6’-H), 8.16 (1H, d, J = 2 Hz, Ar-H), 8.71 (1H, d, J = 2 Hz, Ar-H) ppm. 13C NMR (CDCl3, 75.4 MHz): 
δ 51.74 (OMe), 55.34 (OMe), 84.90 (C), 94.17 (C), 100.63 (2-C), 114.16 (3’and 5’-CH), 114.28 (C), 
119.52 (C), 133.25 (CH), 133.29 (2’ and 6’-CH), 133.78 (C), 144.56 (C), 147.27 (C), 148.56 (CH), 
160.20 (C), 165.18 (C=O) ppm. MS (EI): m/z (%) 338 (M+, 100), 306 (39). HRMS M+  C18H14N2O3S: 
caldt. 338.0725; found 338.0724. 
 
 
4.1.1.5. Methyl 3-amino-6-[2-(2-aminophenyl)ethynyl]thieno[3,2-b]pyridine-2-carboxylate (2e): 
Yellow solid (122 mg, 70%), m.p. 168-170 ºC. 1H NMR (DMSO-d6, 400 MHz) δ 3.82 (3H, s, OMe), 5.68 
(2H, br s, NH2), 6.52-6.57 (1H, m, Ar-H), 6.73 (1H, br d, J = 9.2 Hz, Ar-H), 6.93  (2H, br s, 2’-NH2), 
7.08-7.14 (1H, m, Ar-H), 7.26 (1H, dd, J =  7.6 and 1.6 Hz, Ar-H), 8.63 (1H, d, J = 1.6 Hz, Ar-H), 8.85 
(1H, d, J = 1.6 Hz, Ar-H) ppm. 13C NMR (DMSO-d6, 100.6 MHz) δ 51.57 (OMe), 90.88 (C), 91.60 (C), 
97.94 (2-C), 104.38 (C), 114.03 (CH), 115.69 (CH), 119.02 (C), 130.46 (CH), 131.89 (CH), 132.97 (C), 
133.50 (CH), 144.57 (C), 147.77 (C), 148.51 (CH), 150.15 (C), 164.40 (C=O) ppm. Elemental Anal. 
calcd for C17H13N3O2S C, 63.14; H, 4.05; N, 12.99; S, 9.92%. Found C, 63.05; H, 4.05; N, 12.59; S, 
9.48%. 
 
4.1.1.6. Methyl 3-amino-6-[2-(3-aminophenyl)ethynyl]thieno[3,2-b]pyridine-2-carboxylate (2f): 
Yellow solid (105 mg, 60%), m.p. 203-205 ºC. 1H NMR (DMSO-d6, 400 MHz) δ 3.82 (3H, s, OMe), 5.30 
(2H, br s, NH2), 6.64 (1H, ddd, J = 8.1 2.4 and 1.2 Hz, Ar-H), 6.73 (1H, dt, J = 7.6 and 1.2 Hz, Ar-H), 
6.77 (1H, m, Ar-H), 6.92 (2H, br s, NH2), 7.01 (1H, app. t, J = 8 Hz, 5’-H), 8.57 (1H, d, J = 2 Hz, Ar-H), 
8.76 (1H, d, J = 2 Hz, Ar-H) ppm. 13C NMR (DMSO-d6, 100.6 MHz) δ 51.62 (OMe), 84.97 (C), 94.46 
(C), 98.35 (2’-C), 115.17 (4’-CH), 116.14 (2’-CH), 118.42 (C), 118.94 (6’-CH), 121.68 (C), 129.32 (5’-
CH), 133.10 (C), 133.92 (CH), 144.94 (C), 147.65 (C), 148.53 (CH), 148.91 (C), 164.40 (C=O) ppm. MS 
(EI) m/z 323 (M+, 100), 291 (56). HRMS calcd. for C17H13N3O2S M+ 323.0728; found 323.0729. 
 
4.1.1.7. Methyl 3-amino-6-[2-(4-aminophenyl)ethynyl]thieno[3,2-b]pyridine-2-carboxylate (2g): 
Yellow solid (130 mg, 75%), m.p. 211-213 ºC. 1H NMR (DMSO-d6, 300 MHz) δ 3.81 (3H, s, OMe), 5.70 
(2H, br s, NH2), 6.57 (2H, d, J = 8.4 Hz, 3’ and 5’-CH), 6.91 (2H, br s, NH2), 7.25 (2H, d, J = 8.4 Hz, 2’ 
and 6’-CH), 8.46 (1H, d, J = 2  Hz, Ar-H), 8.70 (1H, d, J = 2 Hz, Ar-H) ppm. 13C NMR (DMSO-d6, 75.4 
MHz) δ 51.60 (OMe), 83.87 (C), 96.06 (C), 97.85 (2-C), 107.07 (C), 113.62 (3’ and 5’-CH), 119.43 (C), 
132.92 (2’ and 6’-CH), 132.97 (CH), 133.22 (C), 144.33 (C), 147.77 (C), 148.29 (CH), 150.15 (C), 
164.46 (C=O) ppm. MS (EI) m/z 323 (M+, 100), 291 (51). HRMS calcd. for C17H13N3O2S M+ 323.0728; 
found 323.0727. 
 
4.1.1.8. Methyl 3-amino-6-{2-[4-(dimethylamino)phenyl]ethynyl}thieno[3,2-b]pyridine-2-
carboxylate (2h): Green solid (152 mg, 80%), m.p. 191-193 ºC. 1H NMR (DMSO-d6, 300 MHz) δ 2.96 
(6H, s, 2×Me), 3.81 (3H, s, OMe), 6.73 (2H, d, J = 8.7 Hz, 3’ and 5’-CH), 6.92 (2H, br s, NH2), 7.40 (2H, 
d, J = 8.7 Hz, 2’ and 6’-CH), 8.49 (1H, d, J = 2 Hz, Ar-H), 8.72 (1H, d, J = 2 Hz, Ar-H) ppm. 13C NMR 
(DMSO-d6, 75.4 MHz) δ 39.59 (2×Me), 51.56 (OMe), 84.51 (C), 95.60 (C), 97.86 (2-C), 107.33 (1’C), 
111.79 (3’ and 5’-CH), 119.24 (C), 132.66 (2’ and 6’-CH), 133.05 (CH), 133.16 (C), 144.36 (3a-C), 
147.72 (C), 148.28 (CH), 150.44 (4’-C), 164.41 (C=O) ppm. MS (EI) m/z 351 (M+, 100), 319 (33). 
HRMS calcd. for C19H17N3O2S  M+ 351.1041; found 351.1042. 
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4.1.1.9. Methyl 3-amino-6-[2-(2-fluorophenyl)ethynyl]thieno[3,2-b]pyridine-2-carboxylate (2i): 
Yellow solid (132 mg, 75%), m.p. 174-176 ºC. 1H NMR (CDCl3, 400 MHz) δ 3.93 (3H, s, OMe), 6.22 
(2H, br s, NH2), 7.14-7.18 (2H, m, Ar-H), 7.35-7.41 (1H, m, Ar-H), 7.53-7.58 (1H, m, Ar-H), 8.21 (1H, d, 
J = 2 Hz, Ar-H), 8.75 (1H, d, J = 2 Hz, Ar-H) ppm. 13C NMR (CDCl3, 100.6 MHz) δ 51.75 (OMe), 87.10 
(C), 91.03 (C), 101.00 (2-C), 111.06 (d, J = 16 Hz, C), 115.68 (d, J = 21 Hz, CH), 118.68 (C), 124,12 (d, 
J = 3 Hz, CH), 130.78 (d, J = 8 Hz, CH), 133.53 (d, J = 13 Hz, CH), 133.63 (CH), 145.29 (C), 147.31 
(C), 148.77 (CH), 162.73 (d, J = 251 Hz, C-F), 165.16 (C=O) ppm. Elemental Analysis calcd. for 
C17H11FN2O2S C, 62.57; H, 3.40; N, 8.58; S, 9.83%. Found C, 62.39; H, 3.43; N, 8.40; S, 9.43%. 
 
4.1.1.10. Methyl 3-amino-6-[2-(4-fluorophenyl)ethynyl]thieno[3,2-b]pyridine-2-carboxylate (2j): 
Yellow solid (159 mg, 90%) m.p. 167-169 ºC. 1H NMR (CDCl3, 400 MHz) δ 3.93 (3H, s, OMe), 6.23 
(2H, br s, NH2), 7.07-7.11 (2H, m, Ar-H), 7.54-7.58 (2H, m, Ar-H), 8.17 (1H, d, J = 2 Hz, Ar-H), 8.71 
(1H, d, J = 2 Hz, Ar-H) ppm. 13C NMR (CDCl3, 100.6 MHz) δ 51.76 (OMe), 85.83 (C), 92.75 (C), 
100.89 (2-C), 115.88 (d, J = 21 Hz, 3’ and 5’-CH), 118.43 (d, J = 3 Hz, C), 118.92 (C), 133.42 (CH), 
133.70 (d, J = 10 Hz, 2’ and 6’-CH ), 133.76 (C), 145.07 (C), 147.29 (C), 148.69 (CH), 162.92 (d, J = 
252 Hz, C-F), 165.17 (C=O) ppm. Elemental Analysis calcd. for C17H11FN2O2S C, 62.57; H, 3.40; N, 
8.58; S, 9.83%. Found C, 62.25; H, 3.53; N, 8.24; S, 9.99%.  
 
4.1.1.11. Methyl 3-amino-6-[2-(pyridin-2-yl)ethynyl]thieno[3,2-b]pyridine-2-carboxylate (2k): 
Yellow solid (117 mg, 70%), m.p. 226-228 ºC. 1H NMR (DMSO-d6, T = 60 ºC, 300 MHz) δ 3.84 (3H, s, 
OMe), 6.81 (2H, br s, NH2), 7.42-7.47 (1H, m, Ar-H), 7.70 (1H, d, J = 7.8 Hz, Ar-H), 7.85-7.91 (1H, m, 
Ar-H), 8.63-8.66 (2H m, Ar-H), 8.84 (1H, d, J = 2 Hz, Ar-H) ppm. 13C NMR (DMSO-d6, T = 60 ºC, 75.4 
MHz) δ 51.33 (OMe), 85.03 (C), 92.47 (C), 99.06 (2-C), 117.04 (C), 123.66 (CH), 127.33 (CH), 132.83 
(C), 134.32 (CH), 136.54 (CH), 141.52 (C), 145.33 (C), 147.22 (C), 148.43 (C), 150.01 (CH), 164.08 
(C=O) ppm. MS (EI) m/z 309 (M+, 100), 277 (63). HRMS calcd. for C16H11N3O2S  M+ 309.0572; found 
309.0571. 
 
4.1.1.12. Methyl 3-amino-6-[2-(pyridin-3-yl)ethynyl]thieno[3,2-b]pyridine-2-carboxylate (2l): 
Yellow solid (150 mg, 90%), m.p. 205-207 ºC. 1H NMR (CDCl3, 400 MHz) δ 3.93 (3H, s, OMe), 6.22 
(2H, br s, NH2), 7.36-7.38 (1H, m, Ar-H), 7.44-7.50 (1H, m, Ar-H), 7.64-7.70 (1H, m, Ar-H), 7.87 (1H, d, 
J = 8 Hz, Ar-H), 8.21 (1H,d, J = 2 Hz, Ar-H), 8.74 (1H, d, J = 2 Hz, Ar-H) ppm. 13C NMR (CDCl3, 100.6 
MHz): δ 51.78 (OMe), 89.52 (C), 90.08 (C), 101.18 (2-C), 118.18 (C), 119.78 (C), 123.29 (CH), 128.55 
(C), 132.02 (CH), 133.61 (C), 133.65 (CH), 138.78 (CH), 145.54 (C), 147.27 (C), 148.74 (CH), 165.13 
(C=O) ppm. MS (EI) m/z 309 (M+, 53), 277 (100). HRMS calcd. for C16H11N3O2S  M+ 309.0572; found 
309.0578. 
 
4.1.1.13. Methyl 3-amino-6-[2-(thien-3-yl)ethynyl)]thieno[3,2-b]pyridine-2-carboxylate (2m): Yellow 
solid (119 mg, 70%), m.p. 165-167 ºC. 1H NMR (CDCl3, 400 MHz) δ 3.93 (3H, s, OMe), 6.22 (2H, br s, 
NH2), 7.24 (1H, dd, J = 4.8 and 1.2 Hz, Ar-H),  7.35 (1H, dd, J = 4.8 and  2.8 Hz, Ar-H), 7.62 (1H, dd, J 
= 2.8 and 1.2 Hz, Ar-H), 8.16 (1H, d, J = 2 Hz, Ar-H), 8.71 (1H, d, J = 2 Hz, Ar-H) ppm. 13C NMR 
(CDCl3, 75.4 MHz) δ 51.74 (OMe), 85.72 (C), 89.05 (C), 100.78 (2-C), 119.09 (C), 121.40 (C), 125.76 
(CH), 129.74 (2 × CH), 133.32 (CH), 133.70 (C), 144.97 (C), 147.32 (C), 148.68 (CH), 165.18 (C=O) 
ppm. MS (EI) m/z 314 (M+, 100), 282 (90). HRMS calcd. for C15H10N2O2S2  M+ 314.0184; found 
314.0183. 
 
 
 
4.2 Biological activity 
4.2.1. Material and Methods 
 
4.2.1.1. Reagents 
Fetal bovine serum (FBS), L-glutamine, phosphate buffered saline (PBS) and trypsin were from Gibco 
Invitrogen Co. (Scotland, UK). RPMI-1640 medium was from Cambrex (New Jersey, USA). Acetic acid, 
dimethyl sulfoxide (DMSO), doxorubicin, penicillin, streptomycin, ethylenediaminetetraacetic acid 
(EDTA), sulforhodamine B (SRB) and trypan blue were from SigmaChemical Co. (Saint Louis, USA). 
Tricloroacetic acid (TCA) and Tris were sourced from Merck (Darmstadt, Germany).  
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4.2.1.2. Solutions of the compounds 
Stock solutions of the tested compounds were prepared in DMSO and kept at −70°C. Appropriate 
dilutions were freshly prepared in the test medium just prior to the assays. The effect of the vehicle 
solvent (DMSO) on the growth of the cell lines was evaluated by exposing untreated control cells to the 
maximum concentration of DMSO used in the assays (0.25%). No influence was found (data not shown). 
 
4.2.1.3. Cell cultures 
Three human tumor cell lines, MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer) 
and A375-C5 (melanoma) were used. MCF-7 and A375-C5 were obtained from the European Collection 
of Cell Cultures (ECACC, Salisbury, UK), and NCI-H460 was kindly provided by the National Cancer 
Institute (NCI, Bethesda, USA). They were routinely maintained as adherent cell cultures in RPMI-1640 
medium supplemented with 5% heat-inactivated FBS, 2 mM glutamine and antibiotics (penicillin 100 
U/mL, streptomycin 100 µg/mL), at 37°C in a humidified atmosphere containing 5% CO2. Exponentially 
growing cells were obtained by plating 1.5×105cells/mL for MCF-7 and 0.75×105cells/mL for A375-C5 
and NCI-H460, followed by a 24-h incubation. 
 
4.2.1.4. Growth inhibition assay 
The effects on the in vitro growth of human tumor cell lines were evaluated according to the procedure 
adopted by the NCI (USA) in their “In vitro Anticancer Drug Discovery Screen”, using the protein-
binding dye sulforhodamine B to assess cell growth.[8,9] Briefly, exponentially growing cells were 
exposed for 48 h, in 96-well microtiter plates, to five serial dilutions of each test compound, starting from 
a maximum concentration of 150 µM (if possible). Following the exposure period adherent cells were 
fixed in situ with TCA, washed and stained with SRB. The bound stain was solubilized and the 
absorbance was measured at 492 nm in a plate reader (Bio-tek Instruments Inc., Powerwave XS, 
Wincoski, USA). Dose-response curves were obtained for each test compound and cell line, and the 
growth inhibition of 50% (GI50), corresponding to the concentration of the compounds that inhibited 50% 
of the net cell growth was calculated as described elsewhere.[9] Doxorubicin was tested in the same 
manner, to be used as a positive control. 
 
4.2.1.5. Flow cytometric assays for cell cycle distribution analysys and apoptosis detection with 
annexin V-FITC/PI assay 
NCI-H460 cells were plated at 0.75×105cells/mL in 6-well plates and left incubating for 24 h. Cells were 
then incubated with complete medium only (control), medium with the compound’s solvent (DMSO) or 
with compounds 2d, 2e and 2g at their respective GI50 concentrations previously obtained by the SRB 
assay (0.32, 5.7 and 8.9 µM). Cells were harvested following a 48 h incubation with the compounds and 
further processed for either cell cycle analysis or apoptosis detection. For cell cycle analysis, cells were 
fixed in 70 % ethanol and subsequently resuspended in PBS containing 0.1 mg/mL RNase A and 5 µg/mL 
propidium iodide, prior to analysis. Induced apoptosis was assayed by the Human Annexin V-FITC/PI 
apoptosis Kit (Bender MedSystems, Vienna, Austria) according to the manufacturer’s instructions.[10] 
Cellular DNA content (for cell cycle distribution analysis and presence of sub-G1 peak, suggestive of 
apoptosis induction) and measurement of phosphatidylserine externalization were analyzed using an 
Epics XL-MCL Coulter flow cytometer plotting at least 20,000 events per sample. Cell cycle distribution 
and apoptosis data analysis was subsequently performed using FlowJo 7.2 software (Tree Star, Inc.). 
Experiments were performed in duplicate in three to six independent occasions and the average and 
standard error of the obtained results were presented. Statistical analysis was performed for the induction 
of apoptosis results by the non-parametric Friedman’s test followed by Dunn’s Post-test using GraphPad 
Prism 5 software. P values < 0.05 were considered as statistically significant.  
 
 
Acknowledgments 
 
To the Foundation for Science and Technology (FCT, Portugal) through the financial support to the 
research centres, the national NMR network (Bruker Avance III 400) REDE/1517/RMN/2005, the 
research project PTDC/QUI-QUI/111060/2009 which is also financed by COMPETE/QREN/EU. RCC 
and LAVS acknowledge FCT for their PhD (SFRH/BD/29274/2006) and post-doctoral 
(SFRH/BPD/29112/2006) grants, respectively. GMA is supported by FCT and the European Social Fund. 
IPATIMUP is an Associate Laboratory of the Portuguese Ministry of Science, Technology and Higher 
Education and is partially supported by FCT. 
 
 
  11
 
 
References 
 
[1] M. J. Munchhof, J. S. Beebe, J. M. Casavant, B. A. Cooper, J. L. Doty, R. C. Hidgon, S. M. 
Hillerman, C. I. Doderstrom, E. A. Knauth, M. A. Marx, A. M. K. Rossi, S. B. Sobolov, J. Sun, Bioorg. 
Med. Chem. Lett. 14 (2004) 21-24. 
[2] S. Claridge, F. Raeppel, M.-C. Granger, N. Bernstein, O. Saavedra, L. Zhan, D. Llewellyn, A. 
Wahhab, R. Deziel, J. Rahil, N. Beaulieu, H. Nguyen, I. Dupont, A. Barsalou, C. Beaulieu, I. Chute, S. 
Gravel, M.-F. Robert, S. Lefebvre, M. Dubay, R. Pascal, J. Gillespie, Z. Jin, J. Wang, J.M. Besterman, A. 
R. MacLeod; A. Vaisburg, Bioorg. Med. Chem. Lett. 18 (2008) 2793-2798. 
[3] S. Raeppel, S. Claridge, O. Saavedra, F. Gaudette, L. Zhan, M. Mannion, N. Zhou, F. Raeppel, M.-C. 
Granger, L. Isakovick, R. Deziel, H. Nguyen, N. Beaulieu, C. Beaulieu, I. Dupont, M.-F. Robert, S. 
Lefebvre, M. Dubay, J. Rahil, J. Wang, H. Ste-Croix, A. R. MacLeod, J.Besterman, A. Vaisburg, Bioorg. 
Med. Chem. Lett. 19 (2009) 1323-1328. 
[4] D. H. Boschelli, B. Wu, A. C. B. Susa, H. Durutlic, F. Ye, Y. Raifeld, J. M. Golas, F. Boschelli, J. 
Med. Chem. 47 (2004) 6666-6668.  
[5] R. C. Calhelha, M.-J. R. P. Queiroz,  Tetrahedron Lett. 51 (2010) 281-283. 
[6] For a recent review on the Sonogashira reaction see: R. Chincilla, C. Nájera Chem. Rev. 107 (2007) 
874-922. 
[7] M.-J. R. P. Queiroz, R. C. Calhelha, L. A. Vale-Silva, E. Pinto, M. S.-J. Nascimento, Eur. J. Med. 
Chem. 44 (2009) 1893-1899. 
[8] P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. T. Warren, H. Bokesch, S. 
Kenney, M. R. Boyd, J. Natl. Cancer Inst. 83 (1991) 757-776. 
[9] A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose, J.  Langley, P. 
Cronise, A. Vaigro-Wolff, M. Gray-Goodrich, H. Campbell, J. Mayo, M. Boyd, J. Natl. Cancer Inst. 83 
(1991) 757-776. 
[10] G. M. Almeida, T. L. Duarte, P. B. Farmer, W. P. Steward, G. D. D. Jones,  Int. J. Cancer 122 (2008) 
1810-1819. 
 
